Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kallappa Koti

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data in biologic oncology productsMark D Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Journal of Biopharmaceutical Statistics|August 21, 2013
Evaluating and adjusting for premature censoring of progression-free survivalMark Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimensRuthann M Giusti, Kaushikkumar Shastri, Anne M Pilaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphomaR Angelo de Claro, Karen McGinn, Virginia Kwitkowski, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data in biologic oncology productsMark D Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Journal of Biopharmaceutical Statistics|August 21, 2013
Evaluating and adjusting for premature censoring of progression-free survivalMark Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimensRuthann M Giusti, Kaushikkumar Shastri, Anne M Pilaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphomaR Angelo de Claro, Karen McGinn, Virginia Kwitkowski, et al.
Pageof 1